entity

transcytosis

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about transcytosis: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

5Connections
12Hypotheses
3Analyses
1Outgoing
4Incoming
0Experiments
3Debates

No AI portrait yet

Outgoing (1)

TargetRelationTypeStr
amyloid-betaregulatesprotein0.85

Incoming (4)

SourceRelationTypeStr
TFRCinvolved_ingene0.90
caveolin_1enhancesprotein0.80
TfR1_clusteringactivatesmechanism0.70
LRP1mediatesprotein0.70

Targeting Hypotheses (12)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
LRP1-Mediated Transcytosis for CNS Antibody Delivery 0.680 neurodegeneration Blood-brain barrier antibody transport m
CSF/Serum NfL Ratio Discriminates Active Transcytosis from P 0.665 - What blood-brain barrier permeability ch
LDLR Ligand-Binding Domain A Fusion for Receptor-Mediated Tr 0.650 neurodegeneration Blood-brain barrier antibody transport m
Fusing IGFBPL1 to IGF-1 for Receptor-Mediated BBB Transcytos 0.552 drug-delivery Can IGFBPL1 therapeutics effectively cro
C1q-Targeted miR-33 ASO Delivery for APOE4 Hyper-Lipidation 0.427 molecular-biology Is APOE4's reduced lipid binding pathoge
Tau propagation through muscarinic receptor-mediated BBB tra 0.400 neurodegeneration Test
LDLR-Primed LRP1 Transcytosis with Endosomal Liberation Stra 0.380 neuropharmacology What is the actual quantitative contribu
LDLR-Primed LRP1 Transcytosis with pH-Activated Endosomal Es 0.380 neuropharmacology What is the actual quantitative contribu
endothelial transcytosis defines the therapeutic window for: 0.357 neurodegeneration Blood-brain barrier permeability changes
C1q-Alectinib Complexation Facilitates Brain Penetration via 0.161 molecular-biology Does Alectinib truly bind C1q directly w
LDLR-Primed LRP1 Transcytosis with pH-Responsive Escape Stra 0.000 neuropharmacology What is the actual quantitative contribu
Bi-directional Transcytosis Inhibition Strategy 0.000 - Blood-brain barrier transport mechanisms

Mentioning Analyses (3)

Scientific analyses that reference this entity

What determines blood-brain barrier penetration kinetics for specialized pro-res

neuropharmacology | 2026-04-13 | 2 hypotheses Top: 0.551

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 14 hypotheses Top: 0.773

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (18)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Crossing the blood-brain barrier: emerging therapeutic strategies for neurologic [PMID:39862873] Pedder JH, Sonabend AM, Cearns MD Lancet Neurol 2025 0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] ["Chen Kai", "Li Fuyao", "Zhang Shuwen", Journal of neuroinflammation 2025 0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] ["Chen Kai", "Li Fuyao", "Zhang Shuwen", Journal of neuroinflammation 2025 0
Post-Ischemic Neurodegeneration of the Hippocampus Resembling Alzheimer's Diseas [PMID:35008731] Unknown International journal of molec 2022 0
Post-Ischemic Neurodegeneration of the Hippocampus Resembling Alzheimer's Diseas [PMID:35008731] Pluta, Januszewski, Czuczwar International journal of molec 2022 0
Strategies for delivering therapeutics across the blood-brain barrier. [PMID:33649582] Terstappen GC, Meyer AH, Bell RD Nat Rev Drug Discov 2021 0
Strategies for delivering therapeutics across the blood-brain barrier. [PMID:33649582] ["Terstappen GC", "Meyer AH", "Bell RD"] Nat Rev Drug Discov 2021 0
A blood-brain barrier overview on structure, function, impairment, and biomarker [PMID:33208141] Kadry, Noorani, Cucullo Fluids and barriers of the CNS 2021 0
CD38 in Neurodegeneration and Neuroinflammation. [PMID:32085567] Guerreiro S, Privat AL, Bressac L, Toulo Cells 2020 0
Lung Endothelial Transcytosis. [PMID:32163197] Jones JH, Minshall RD Compr Physiol 2020 0
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554] Marogianni C, Sokratous M, Dardiotis E, International journal of molec 2020 0
A blood-brain barrier overview on structure, function, impairment, and biomarker [PMID:33208141] Kadry H, Noorani B, Cucullo L Fluids Barriers CNS 2020 0
CD38 in Neurodegeneration and Neuroinflammation. [PMID:32085567] Guerreiro S, Privat AL, Bressac L, Toulo Cells 2020 0
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554] Marogianni C, Sokratous M, Dardiotis E, International journal of molec 2020 0
Increased brain penetration and potency of a therapeutic antibody using a monova [PMID:24411731] Niewoehner J, Bohrmann B, Collin L Neuron 2014 0
Increased brain penetration and potency of a therapeutic antibody using a monova [PMID:24411731] ["Niewoehner J", "Bohrmann B", "Collin L Neuron 2014 0
Neurodegeneration. [PMID:12938729] Burgunder IUBMB life 2004 0
Neurodegeneration. [PMID:12938729] Unknown IUBMB Life 2003 0

Debates (3)

Multi-agent debates referencing this entity

The debate highlighted BBB penetration as a major hurdle for SPM therapeutics bu

closed · Rounds: 4 · Score: 0.66 · 2026-04-13

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

closed · Rounds: 4 · Score: 0.91 · 2026-04-06

What are the mechanisms underlying blood-brain barrier transport mechanisms for

closed · Rounds: 4 · Score: 0.94 · 2026-04-01

Related Research

Hypotheses and analyses mentioning transcytosis in their description or question text

Tau propagation through muscarinic receptor-mediated BBB transcytosis

Score: 0.400 · neurodegeneration · 2026-04-29

The hypothesis proposes that pathological tau enters or spreads through the CNS via M1/M3 muscarinic receptor-mediated B

LDLR-Primed LRP1 Transcytosis with Endosomal Liberation Strategy

Score: 0.380 · neuropharmacology · 2026-04-27

This strategy combines LDLR upregulation-mediated cholesterol transport machinery priming with engineered endosomal esca

LDLR-Primed LRP1 Transcytosis with pH-Activated Endosomal Escape

Score: 0.380 · neuropharmacology · 2026-04-27

This strategy combines LDLR upregulation in brain endothelial cells with engineered LRP1-targeting antibodies containing

endothelial transcytosis defines the therapeutic window for: Blood-brain barrier

Score: 0.357 · neurodegeneration · 2026-04-26

The same signal may be beneficial early and damaging late. Testing endothelial transcytosis with pericyte-protective dos

C1q-Alectinib Complexation Facilitates Brain Penetration via Receptor-Mediated T

Score: 0.161 · molecular-biology · 2026-04-18

## Mechanistic Overview C1q-Alectinib Complexation Facilitates Brain Penetration via Receptor-Mediated Transcytosis star

LDLR-Primed LRP1 Transcytosis with pH-Responsive Escape Strategy

Score: 0.000 · neuropharmacology · 2026-04-28

This strategy combines targeted upregulation of LDLR expression in brain endothelial cells with engineered antibodies de

Bi-directional Transcytosis Inhibition Strategy

Score: 0.000 · unknown disease · 2026-04-28

Combine improved BBB-penetrating anti-amyloid antibodies with selective inhibitors of P-glycoprotein and other efflux tr